Lecithin as a therapeutic agent in Ulcerative Colitis

• Verfasst von: Stremmel, Wolfgang [VerfasserIn]
• Verfasst von: Gauss, Annika [VerfasserIn]
• Titel: Lecithin as a therapeutic agent in Ulcerative Colitis
• Verf.angabe: Wolfgang Stremmel, Annika Gauss
• Jahr: 2013
• Umfang: 3 S.
• Fussnoten: Gesehen am 15.03.2022
• Titel Quelle: Enthalten in: Digestive diseases
• Ort Quelle: Basel : Karger, 1983
• Jahr Quelle: 2013
• Band/Heft Quelle: 31(2013), 3-4, Seite 388-390
• ISSN Quelle: 1421-9875
• DOI: doi:10.1159/000354707
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1795584726

Abstract

Lecithin [phosphatidylcholine (PC)] was shown to account for more than 70% of total phospholipids within the intestinal mucus layer. It is arranged in lamellar membranes (surfactant-like particles) and establishes a hydrophobic barrier preventing invasion of the colonic commensal microbiota. In ulcerative colitis (UC), the mucus PC content was demonstrated to be reduced by about 70%, irrespective of the presence of inflammation. This may be of primary pathogenetic significance allowing bacteria to enter the mucus and induce mucosal inflammation. Therefore, a new therapeutic strategy is being developed to substitute the missing mucus PC content in UC. Indeed, a delayed-release PC formulation was able to compensate the lack of PC and improve the inflammatory activity. In randomized controlled studies, delayed-release PC was proven to be clinically and endoscopically effective, which now awaits a phase III authority approval trial.